5.3 Antipsychotics and treatment of schizophrenia

Antipsychotics are the primary pharmacological treatment for schizophrenia, a chronic psychiatric disorder characterized by disturbances in thought, perception, and behavior. These drugs work mainly by modulating dopamine and serotonin signaling in the brain, which helps control symptoms like hallucinations and delusions.

Understanding how these drugs differ in mechanism, efficacy, and side effects is central to choosing the right agent for a given patient. This section covers the two main classes of antipsychotics, the neurotransmitter theory behind schizophrenia, key therapeutic uses and monitoring requirements, and the non-pharmacological strategies that complement drug therapy.

Typical vs Atypical Antipsychotics

Mechanisms of Action

Typical (first-generation) antipsychotics primarily block dopamine $D_2$ receptors. They affect multiple dopamine pathways in the brain, which is why they're effective against positive symptoms but also cause significant movement-related side effects. Examples include haloperidol and chlorpromazine.

Atypical (second-generation) antipsychotics block both dopamine $D_2$ receptors and serotonin $5\text{-HT}_{2A}$ receptors. This dual action gives them a broader pharmacological profile. The serotonin blockade is thought to "loosen" dopamine blockade in certain pathways, which is why atypicals tend to cause fewer movement side effects. Examples include risperidone, olanzapine, and quetiapine.

A key pharmacological difference: atypical antipsychotics have a wider therapeutic window between the dose needed for antipsychotic effect and the dose that triggers extrapyramidal symptoms (EPS). This allows more dosing flexibility in clinical practice.

Side Effect Profiles

The side effect trade-off between the two classes is one of the most tested concepts here:

• Typical antipsychotics carry a higher risk of extrapyramidal symptoms (EPS) because of their strong $D_2$ blockade. EPS includes:
  • Akathisia (restlessness, inability to sit still)
  • Acute dystonia (involuntary muscle contractions, often in the neck or jaw)
  • Tardive dyskinesia (repetitive, involuntary movements, often of the face and tongue, that can become irreversible)
• Atypical antipsychotics generally have lower EPS risk but are more likely to cause metabolic side effects:
  • Weight gain
  • Type 2 diabetes
  • Hyperlipidemia (elevated cholesterol and triglycerides)

Clozapine deserves special attention. It's an atypical antipsychotic with unique efficacy for treatment-resistant schizophrenia (patients who haven't responded to at least two other antipsychotics). However, it carries a risk of agranulocytosis, a dangerous drop in white blood cells that can be fatal if undetected. Because of this, clozapine requires mandatory blood monitoring with specific protocols dictating how often white blood cell counts are checked and when dose adjustments or discontinuation are necessary.

Dopamine and Serotonin in Schizophrenia

Dopamine Hypothesis

The dopamine hypothesis is the foundational model for understanding schizophrenia pharmacology. It proposes that schizophrenia symptoms arise from dopamine imbalances in specific brain pathways:

• Mesolimbic pathway (projects from the ventral tegmental area to the limbic system): Excessive dopamine activity here is linked to positive symptoms such as hallucinations, delusions, and disorganized thinking. Antipsychotics reduce positive symptoms by blocking $D_2$ receptors in this pathway.
• Mesocortical pathway (projects from the ventral tegmental area to the prefrontal cortex): Reduced dopamine activity here is associated with negative symptoms (flat affect, social withdrawal, lack of motivation) and cognitive deficits (poor working memory, impaired attention).

This creates a pharmacological dilemma: blocking $D_2$ receptors helps the mesolimbic overactivity but can worsen the mesocortical underactivity. That's one reason negative symptoms are harder to treat with typical antipsychotics.

Serotonin Involvement

Serotonin dysregulation, particularly its interaction with dopamine systems, also plays a role in schizophrenia. Atypical antipsychotics block $5\text{-HT}_{2A}$ receptors, which has two important consequences:

• It may improve efficacy against negative symptoms, partly by increasing dopamine release in the mesocortical pathway (counteracting the mesocortical deficit)
• It helps reduce EPS by modulating dopamine transmission in the nigrostriatal pathway

Neurotransmitter Balance

The overall efficacy and side effect profile of any antipsychotic depends on how it balances dopamine and serotonin modulation. But these aren't the only neurotransmitters involved. Many antipsychotics also affect:

• Histamine receptors ($H_1$ blockade causes sedation and weight gain)
• Muscarinic acetylcholine receptors (blockade causes dry mouth, constipation, urinary retention, blurred vision)
• Alpha-1 adrenergic receptors (blockade causes orthostatic hypotension)

These "off-target" receptor effects explain much of the side effect variation you see between individual drugs within each class.

Antipsychotic Therapy: Uses and Risks

Therapeutic Applications

Antipsychotics are first-line for schizophrenia, but they also have approved uses in:

• Bipolar disorder (both acute mania and maintenance)
• Major depressive disorder (as adjunctive therapy)
• Other psychiatric conditions, including severe agitation and certain anxiety disorders

Common adverse effects across the class include sedation, weight gain, sexual dysfunction, and orthostatic hypotension. The severity varies significantly between individual agents, which is why drug selection often comes down to matching a patient's risk profile with a drug's side effect profile.

Monitoring Requirements

Patients on antipsychotics need regular monitoring. Here's what to track and why:

• Metabolic panel (especially for atypical agents):
  • Weight and BMI
  • Fasting blood glucose
  • Lipid profiles (cholesterol, triglycerides)
• Extrapyramidal symptoms: Regular assessment using standardized rating scales, particularly for patients on typical antipsychotics (though some atypicals like risperidone can also cause EPS at higher doses)
• White blood cell count: Mandatory for clozapine due to agranulocytosis risk, with specific frequency protocols
• ECG monitoring: Recommended for certain antipsychotics (e.g., ziprasidone, thioridazine) that can prolong the QT interval, increasing the risk of dangerous cardiac arrhythmias
• Prolactin levels: Some antipsychotics (especially typical agents and risperidone) cause hyperprolactinemia, which can lead to sexual dysfunction, menstrual irregularities, and long-term risk of osteoporosis

Non-Pharmacological Interventions for Schizophrenia

Medication alone is rarely sufficient for managing schizophrenia. Non-pharmacological interventions improve functional outcomes, treatment adherence, and quality of life. These are used alongside antipsychotic therapy, not as replacements.

Psychosocial Interventions

• Cognitive Behavioral Therapy (CBT) for psychosis: Helps patients identify and challenge dysfunctional thought patterns (e.g., paranoid beliefs) and modify behaviors associated with their symptoms. Evidence supports its use as an adjunct to medication.
• Social skills training: Targets deficits in interpersonal functioning through structured practice of communication and daily living skills, improving community integration.
• Family psychoeducation: Educates patients and their families about the illness, treatment expectations, and relapse warning signs. Programs that include families consistently show improved medication adherence and reduced relapse rates.

Community-Based Support

• Supported employment programs: Help individuals obtain and maintain competitive jobs rather than sheltered work settings, promoting functional recovery.
• Assertive Community Treatment (ACT): An intensive, team-based model that delivers psychiatric services directly in the community. ACT reduces hospitalizations and improves quality of life, especially for patients with severe illness who struggle to engage with traditional outpatient care.
• Peer support programs: Led by individuals with lived experience of mental illness, these provide social support and model recovery-oriented practices.

Cognitive Enhancement

Cognitive remediation therapy directly targets the cognitive deficits common in schizophrenia, including impaired attention, memory, and executive functioning. These cognitive deficits are often the biggest barrier to functional recovery, even when positive symptoms are well controlled by medication. Cognitive remediation uses structured exercises to strengthen these skills over time.